Business
Interim Results for six months ended 31 Dec 2024
Interim Results for six months ended 31 Dec 2024.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\" or the \"Group\")\n \nInterim Results for the six months ended 31 December 2024\n \n \n31 March 2025: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2024.\n \nHighlights\n \nFinancial\n- Operating profit of £1.9 million before R&D, exceptional and fundraising costs (FY2024 H1: £0.5 million operating loss pre-R&D and exceptional costs).\n- Cash position of £21.7 million at 31 December 2024 (30 June 2024: £12.9 million).\n- Financial turnaround progressing with H1 revenues of £34.0 million (FY2024 H1: £33.6 million), 4% growth on a constant currency basis (FY2024 H2: 2% growth).\n- Second consecutive period of half year growth with improved operating margin.\n- Continued focus on cost control, with total administrative expenses reduced by 9.7% against comparative period.\n \nOperational\n- Increase of 5% in volume of units sold reflecting a recovery in manufacturing capacity and improved ability to meet market demand.\n- Submission of Marketing Authorisation Application for Grass MATA MPL in November 2024.\n- First patient treated in the G308 Phase III trial to evaluate long-term efficacy and safety of Grass MATA MPL in paediatric patients.\n- Positive interim analysis data from the Phase I/IIa VLP Peanut PROTECT Trial showing up to 48% reduction in wheal size after skin-prick testing compared to 8% in placebo, indicating significant potential efficacy of the product.\n \n \nManuel Llobet, CEO at Allergy Therapeutics, commented: \"We enter 2025 with clear positive momentum across all aspects of our business. Our return to first-half growth and strengthened financial foundation give us renewed confidence to advance our strategic priorities. The submission of our Marketing Authorisation Application for Grass MATA MPL in Germany and the start of our paediatric G308 trial mark significant progress in our grass allergy programme. Sim...